Bill · H.R. 4570· House(119-HR-4570)
Interagency Patent Coordination and Improvement Act of 2025
- Introduced
- 7/21/2025
- Last activity
- 7/21/2025 — Referred to the House Committee on the Judiciary.
- Sponsored by
- Joe Neguse
- Cosponsors
- None
- Introduced
- In Committee
What this bill would do
This bill, called the "Interagency Patent Coordination and Improvement Act of 2025", aims to improve coordination between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). It establishes an interagency task force to share information and provide technical assistance related to patents, particularly for human drugs and biological products. The goal is to ensure accuracy and consistency in patent-related decisions.
Yes
Does this make patent and copyright rules fairer?+3
This bill could improve intellectual property fairness by ensuring accuracy and consistency in patent-related decisions regarding drugs and biological products.
Does this make what the government does easier for the public to see?+2
The bill promotes government transparency through increased information sharing between the USPTO and FDA.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
More informed patent decisions regarding drugs and biological products: The Interagency Task Force on Patents, established under Section 4, will facilitate the sharing of information between the USPTO and FDA. This could lead to better-informed decisions about patents for human drugs and biological products, potentially impacting the availability and affordability of medications.
-
Increased accuracy and consistency in information: Section 2 highlights that entities submitting patent applications may also share information with other federal agencies. The task force aims to ensure accuracy and consistency in these representations.
Potential Negative Impacts for People
- Potential delays in drug approvals: The information-sharing process and consultations (Sec. 4(f)(2)(B)(i)) could potentially slow down the approval process for new drugs and biological products, as the sponsor of the human drug or biological product will be provided notice of that sharing by the applicable agency and with a period of 30 days to consult with the agency sharing that information.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Education And Technology
- Improves Intellectual Property Fairness+3
- Governance And Ideology
- Improves Government Transparency+2
- 7/21/2025
- Referred to the House Committee on the Judiciary.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.